Orchestra BioMed (OBIO) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| B. Riley Securities | Maintained | Buy | $11.00 from $10.00 | Sep 15, 2026 |
| BTIG | Upgraded | Neutral → Buy | $10.00 | Sep 10, 2026 |
| Piper Sandler | Maintained | Overweight | $10.00 from $9.00 | Aug 11, 2026 |
| B. Riley Securities | Maintained | Buy | $10.00 from $12.00 | May 19, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | May 14, 2026 |
| Barclays | Maintained | Overweight | $13.00 from $12.00 | May 13, 2026 |
| Chardan Capital | Maintained | Buy | $20.00 | Mar 12, 2026 |
| Barclays | Maintained | Overweight | $12.00 from $11.00 | Jan 9, 2026 |
| TD Cowen | Initiated Coverage | Buy | $15.00 | Dec 10, 2025 |
| Chardan Capital | Maintained | Buy | $20.00 | Nov 13, 2025 |
| Barclays | Maintained | Overweight | $11.00 from $12.00 | Nov 12, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 from $12.00 | Sep 4, 2025 |
| BTIG | Downgraded | Buy → Neutral | — | Aug 20, 2025 |
| Chardan Capital | Maintained | Buy | $20.00 | Aug 13, 2025 |
| Chardan Capital | Maintained | Buy | $20.00 | Aug 7, 2025 |
| Chardan Capital | Maintained | Buy | $20.00 | May 13, 2025 |
| Barclays | Maintained | Overweight | $12.00 from $16.00 | May 5, 2025 |
| Chardan Capital | Maintained | Buy | $20.00 | Apr 22, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $12.00 from $14.00 | Apr 4, 2025 |
| Chardan Capital | Maintained | Buy | $20.00 | Apr 1, 2025 |
Frequently asked questions
What is the price target for OBIO stock?
The average 12-month analyst price target for Orchestra BioMed (OBIO) is $10.33, with a high estimate of $11.00 and a low of $10.00, across 3 analysts.
Is OBIO a buy, sell, or hold?
Analysts covering Orchestra BioMed currently average a Buy rating: 6 buy, 1 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for OBIO?
The average price target of $10.33 implies 83.22% upside from the last price of $5.64.
What is the latest analyst rating on OBIO?
On Sep 15, 2026, B. Riley Securities maintained Orchestra BioMed at Buy with a price target of $11.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.